The FDA has approved Revlimid (lenalidomide) for several blood cancers and related conditions. This oral medication is a thalidomide analogue. It is used in combination with other drugs for multiple myeloma, both as treatment and as maintenance therapy after a stem cell transplant. It is also approved for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes with a specific chromosome abnormality (deletion 5q). Additionally, Revlimid is approved for mantle cell lymphoma that has relapsed or progressed after two prior therapies, and for previously treated follicular lymphoma and marginal zone lymphoma when given with a rituximab product.
This approval means that patients with these conditions have a new treatment option that can be taken by mouth. However, Revlimid is not approved for chronic lymphocytic leukemia outside of controlled clinical trials. The drug requires careful monitoring for blood cell count changes and dose adjustments based on kidney function.
If you or a loved one has one of these conditions, talk to your doctor about whether Revlimid might be an appropriate treatment option. Your doctor can help you understand the benefits and risks based on your specific health situation.